Rifamycin SV clinical trials
Also written Rifamycin.
How each study uses rifamycin SV is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the rifamycin SV studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 16 Nov 2018 · AEMCOLO · NDA 210910 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Other names
- Rifamycin
- 2
Studies by the year they started
5 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 2
RedHill Biopharma Limited (2) · Elif Asena KANTARCI (1) · Cosmo Technologies Ltd (1) · Bradley Connor (1)
Studies
Open first, then newest update. How each study uses rifamycin SV is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 YearsNot yet recruitingPhase 2RedHill Biopharma LimitedNCT04027894Written as Rifamycin SV MMX
- Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 YearsNot yet recruitingPhase 2RedHill Biopharma LimitedNCT04026984Written as Rifamycin SV-MMX
- Topical Rifamycin SV for Wound Healing After Sapphire FUE Hair TransplantationCompletedNot applicableElif Asena KANTARCINCT07155408Written as Rifamycin SV Sodium
- Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)Status unknownPhase 2Bradley ConnorNCT04501380Written as AEMCOLO (Rifamycin SV MMX)
- Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-DCompletedPhase 2Cosmo Technologies LtdNCT03099785Written as Rifamycin SV 600mg t.i.d.
Codes
What other systems call rifamycin SV · ClinicalTrials.gg INT002777
- MeSH (NLM) C023808rifamycin SVConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) DU69T8ZZPARIFAMYCINConfirmed FDA, NLM, Wikidata
- RxNorm 35616Confirmed FDA, Wikidata
- Wikidata Q26270990rifamycinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C29406RifamycinOne source FDA
- DrugBank DB11753One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C023808 | rifamycin SV | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | DU69T8ZZPA | RIFAMYCIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 35616 | — | Confirmed FDA, Wikidata |
| Wikidata | Q26270990 | rifamycin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C29406 | Rifamycin | One source FDA |
| DrugBank | DB11753 | — | One source Wikidata |
Also registered as rifamycin sodium (UNII 32086GS35Z · RxNorm 236475).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.